Anthem Biosciences (ANTHEM) Share Price falls 2.12% today to Rs 922.4
- September 16, 2026
- Posted by: Harsh Piplani
- Category: News
Anthem Biosciences Share Price fell to Rs 922.4, down 2.12% today, with market capitalisation at Rs 53,098.43 Cr.
Anthem Biosciences Share Price moved lower today, with the stock ending at Rs 922.4 after declining Rs 20 from the previous close of Rs 942.4. The move leaves Anthem Biosciences Share Price Today at a level that is still near its recent trading range, but the session was clearly softer than the prior close. Market capitalisation stood at Rs 53,098.43 Cr, which places the company in the Large Cap category as supplied. This Anthem Biosciences Stock News update confirms the day’s price event, but the supplied data does not establish a company-specific catalyst. For readers tracking Anthem Biosciences Share Price News, the important point is that the fall happened alongside a wide intraday range and a premium valuation profile that already frames the stock differently from many Healthcare peers. Univest will continue to track the move through price, fundamentals and sector context.
Anthem Biosciences (ANTHEM) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 922.4 |
| Previous Close | Rs 942.4 |
| Today's Move | -Rs 20.00 (-2.12%) |
| Open | Rs 938.8 |
| High | Rs 952.35 |
| Low | Rs 915.2 |
| Turnover | Rs 4.32 crore |
| Market Capitalisation | Rs 53,098.43 crore |
| Market Cap Category | Large Cap |
Anthem Biosciences Share Price Today started at Rs 938.8, moved to an intraday high of Rs 952.35 and a low of Rs 915.2, and closed at Rs 922.4. The stock traded below the previous close of Rs 942.4 by Rs 20, which equals a 2.12% decline. The day’s range between Rs 915.2 and Rs 952.35 shows that the stock moved through a spread of Rs 37.15 during the session. Turnover stood at Rs 4.32 Cr, which is the exact value supplied for the day. In market-cap terms, Anthem Biosciences remains a Large Cap company with market capitalisation of Rs 53,098.43 Cr. For investors following Anthem Biosciences Share Price Fall, the session reads as a clean negative close rather than a flat day. Anthem Biosciences Share Price News therefore centres on the actual price move, not on any unverified explanation. The next section looks at the supplied valuation and financial metrics that shape Anthem Biosciences Stock Analysis.
Anthem Biosciences (ANTHEM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 53,098.43 crore |
| P/E Ratio | 92.21x |
| P/B Ratio | 16.97x |
| ROE | 21.98% |
| ROCE | 29.62% |
| EPS | Rs 10.22 |
| Book Value Per Share | Rs 55.53 |
| Dividend Yield | 0.21% |
Anthem Biosciences has a market capitalisation of Rs 53,098.43 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 92.21x, P/B at 16.97x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 21.98% and ROCE of 29.62%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 10.22, book value per share of Rs 55.53, dividend yield of 0.21%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.74x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 92.21x |
| Benchmark Median P/E | 31.74x |
| Benchmark Average P/E | 47.98x |
| Benchmark P/E Range | 3.29x to 683.37x |
| Company P/B Ratio | 16.97x |
| Benchmark Median P/B | 3.02x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 21.98% |
| Benchmark Median ROE | 11.78% |
| Benchmark Average ROE | 11.19% |
| Company ROCE | 29.62% |
| Benchmark Median ROCE | 13.65% |
| Benchmark Average ROCE | 13.65% |
| Company Market Capitalisation | Rs 53,098.43 crore |
| Benchmark Median Market Cap | Rs 750.5 crore |
| Benchmark Average Market Cap | Rs 14,144.11 crore |
Anthem Biosciences operates in the Healthcare sector and the Pharmaceuticals & Drugs industry, where the supplied benchmark scope covers 200 companies in the same industry. Anthem Biosciences Share Price can be compared with that benchmark on valuation and returns. Its P/E of 92.21 is above the industry median of 31.74 and average of 47.98, while its P/B of 16.97 is also above the median of 3.02 and average of 4.44. On profitability, ROE at 21.98% is above the industry median of 11.78%, and ROCE at 29.62% is above the median and average of 13.65%. The sector dataset also shows company market capitalisation benchmarks ranging from Rs 6.04 Cr to Rs 4,41,957.5 Cr, with a median of Rs 750.5 Cr and an average of Rs 14,144.11 Cr. Against that backdrop, Anthem Biosciences Stock Analysis remains anchored in premium valuation and higher return ratios relative to the supplied industry midpoint. For readers searching Anthem Biosciences Share Price Today, this sector context is useful because it explains how the company is positioned versus the broader Pharmaceuticals & Drugs universe, without assuming any cause for the day’s decline.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,41,957.5 | 36.4 | 5.09 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,47,576 | 83.41 | 13.81 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,233.01 | 84.58 | 20.55 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,670.55 | 24.29 | 4.07 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,10,272.68 | 32.62 | 3.13 | 11.83 | 16 |
Anthem Biosciences Share Price also stands out when viewed beside the supplied listed peers. Its market capitalisation of Rs 53,098.43 Cr is smaller than Sun Pharmaceutical Industries at Rs 4,41,957.5 Cr, Divi’s Laboratories at Rs 2,47,576 Cr and Torrent Pharmaceuticals at Rs 1,89,233.01 Cr, but larger than Zydus Lifesciences at Rs 1,11,670.55 Cr and Cipla at Rs 1,10,272.68 Cr. On valuation, Anthem Biosciences Share Price sits at a P/E of 92.21, above Sun Pharma’s 36.4, Zydus Lifesciences’ 24.29 and Cipla’s 32.62, though below Torrent Pharmaceuticals’ 84.58? No, Anthem is actually above Torrent too. On return ratios, Anthem’s ROE of 21.98% is higher than Sun Pharma’s 14.85%, Divi’s 16.19%, Zydus Lifesciences’ 19.69% and Cipla’s 11.83%, while ROCE of 29.62% is higher than the same peer set. That mix is why Anthem Biosciences Share Price News continues to attract comparison-based interest in Healthcare stock analysis.
Why Investors Are Watching Anthem Biosciences
- Anthem Biosciences Share Price fell 2.12% today to Rs 922.4, after closing below the previous close of Rs 942.4.
- The day’s price moved between Rs 915.2 and Rs 952.35, with turnover at Rs 4.32 Cr.
- Market capitalisation is Rs 53,098.43 Cr, and the stock is classified as Large Cap in the supplied data.
- P/E is 92.21, P/B is 16.97, ROE is 21.98% and ROCE is 29.62%.
- In the Pharmaceuticals & Drugs industry benchmark, Anthem Biosciences is above the median on P/E, P/B, ROE and ROCE.
About Anthem Biosciences
Anthem Biosciences is part of the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied dataset gives the company’s market-cap context, valuation ratios and profitability measures, which are the clearest verified identifiers available for this Anthem Biosciences Stock News update. Its share price behaviour today should therefore be read in the context of a high-multiple listed healthcare company with return ratios above the industry midpoint. For readers following Anthem Biosciences Share Price Live on Univest, these company descriptors are the main factual anchors in the current dataset.
Track Anthem Biosciences Share Price on Univest
Use Anthem Biosciences (ANTHEM) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
You can track Anthem Biosciences Share Price on Univest for live price updates, valuation ratios, shareholding pattern, 52-week levels and market insights. Univest also brings together Anthem Biosciences Stock Analysis, Anthem Biosciences Fundamental Analysis and price action context in one place for easier monitoring.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Anthem Biosciences Share Price fall today?
Ans. Anthem Biosciences Share Price fell 2.12% to Rs 922.4 today, but the supplied data does not establish a company-specific catalyst. The event confirms the price move, the previous close and the day’s intraday range.
What is Anthem Biosciences Share Price Today?
Ans. Anthem Biosciences Share Price Today is Rs 922.4. The stock was down Rs 20, or 2.12%, from the previous close of Rs 942.4, after trading between Rs 915.2 and Rs 952.35.
What is Anthem Biosciences market cap today?
Ans. Anthem Biosciences has a market capitalisation of Rs 53,098.43 Cr in the supplied data. That places it in the Large Cap category and gives context for comparing the stock with Healthcare peers and industry benchmarks.
How does Anthem Biosciences compare on valuation?
Ans. Anthem Biosciences trades at a P/E of 92.21 and a P/B of 16.97. Both are above the same-industry benchmark median of 31.74 times earnings and 3.02 times book value. The company trades at a P/E ratio of 92.21x.
What do Anthem Biosciences profitability ratios show?
Ans. Anthem Biosciences reports ROE of 21.98% and ROCE of 29.62%. Both are above the benchmark median of 11.78% for ROE and 13.65% for ROCE in the supplied industry dataset. ROE stands at 21.98%.
